financetom
Market
financetom
/
Market
/
Vail Resorts, DocuSign And 3 Stocks To Watch Heading Into Friday
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Vail Resorts, DocuSign And 3 Stocks To Watch Heading Into Friday
Jun 6, 2024 11:55 PM

With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:

Wall Street expects J.Jill, Inc. to report quarterly earnings at 99 cents per share on revenue of $154.92 million before the opening bell, according to data from Benzinga Pro. J.Jill shares rose 0.8% to $35.50 in after-hours trading.

Vail Resorts, Inc ( MTN ). reported weaker-than-expected results for its third quarter on Thursday. The company posted quarterly earnings of $9.54 per share, missing market estimates of $10.03 per share. The company's sales came in at $1.28 billion versus expectations of $1.30 billion. Vail Resorts ( MTN ) shares fell 6.2% to $182.00 in the after-hours trading session.

Analysts are expecting Graham Corporation ( GHM ) to post quarterly earnings at 4 cents per share on revenue of $44.50 million. The company will release earnings before the markets open. Graham shares gained 7.4% to $27.99 in after-hours trading.

Check out our premarket coverage here

DocuSign, Inc ( DOCU ). reported better-than-expected earnings for its first quarter and the company's board also authorized a $1 billion increase to its existing stock repurchase program. The company said it sees second-quarter billings in the range of $715 million to $725 million. DocuSign ( DOCU ) shares fell 6.2% to $51.20 in the after-hours trading session.

Zumiez Inc ( ZUMZ ). posted upbeat results for its first quarter on Thursday. The company also said it sees second-quarter net sales of $199 million to $204 million and loss of 30 cents to 40 cents per share. Zumiez ( ZUMZ ) shares declined 3.6% to $18.61 in after-hours trading.

Check This Out: Over $12M Bet On PBF Energy? Check Out These 3 Stocks Insiders Are Buying

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Osisko Gold Royalties Renews Share Buyback; Shares Up 3% in U.S. Premarket
Osisko Gold Royalties Renews Share Buyback; Shares Up 3% in U.S. Premarket
Dec 9, 2024
08:33 AM EST, 12/09/2024 (MT Newswires) -- Osisko Gold Royalties ( OR ) gained 3.2% at last look in NYSE pre-market trading after it announced Monday that it received TSX approval to renew its share buyback program. Under the normal course issuer bid, the company may acquire about 5% of its outstanding common stock, or up to 9.3 million shares,...
Sector Update: Financial
Sector Update: Financial
Dec 9, 2024
08:35 AM EST, 12/09/2024 (MT Newswires) -- Financial stocks were edging higher pre-bell Monday with the Financial Select Sector SPDR Fund (XLF) recently advancing by 0.2%. The Direxion Daily Financial Bull 3X Shares (FAS) was 0.4% higher and its bearish counterpart Direxion Daily Financial Bear 3X Shares (FAZ) was down 0.5%. Apollo Global Management ( APO ) and Santander (SAN)...
Sector Update: Tech
Sector Update: Tech
Dec 9, 2024
08:37 AM EST, 12/09/2024 (MT Newswires) -- Technology stocks were retreating premarket Monday as the Technology Select Sector SPDR Fund (XLK) was down 0.3% and the SPDR S&P Semiconductor ETF (XSD) was 0.2% lower recently. Super Micro Computer ( SMCI ) said Friday it received approval from the Nasdaq for an extension to file its delayed annual and quarterly financial...
Sector Update: Health Care
Sector Update: Health Care
Dec 9, 2024
08:39 AM EST, 12/09/2024 (MT Newswires) -- Health care stocks were steady premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was marginally down and the iShares Biotechnology ETF (IBB) was inactive. Arcellx ( ACLX ) shares were up 8.6% pre-bell Monday after the company said preliminary data from a phase 2 trial of anitocabtagene autoleucel in patients...
Copyright 2023-2026 - www.financetom.com All Rights Reserved